View More Recent Stories

Jun 30, 2016 04:05PM Ligand Pharma (LGND) Receives $4M from Expansion of Two OmniAb License Agreements
Jun 30, 2016 04:02PM Ligand Receives $4 Million from Expansion of Two OmniAb® License Agreements
May 4, 2016 06:08AM Ligand Pharma (LGND) Acquires Economic Rights to CorMatrix Product Offerigs
May 4, 2016 06:00AM Ligand Reports First Quarter 2016 Financial Results
May 4, 2016 05:59AM Ligand Acquires Portfolio of Synthetic Royalty and Milestone Rights from CorMatrix® Cardiovascular for $17.5 Million
Apr 22, 2016 09:00AM Ligand Announces First Quarter 2016 Earnings Reporting Date and Participation in Four Upcoming Investor Conferences
Apr 7, 2016 09:01AM Ligand Pharma (LGND) Announces EC Approval of Revolade as Chronic ITP Treatment in Certain Patients
Apr 7, 2016 09:00AM Revolade® Approved in EU as First in Class Therapy for Children Aged 1 Year and Above with Chronic ITP
Mar 28, 2016 09:03AM Ligand Pharma (LGND), ABBA Therapeutics Enter Antibody Licensing Agreement
Mar 28, 2016 09:00AM Ligand Enters Into OmniAb® Platform License Agreement With ABBA Therapeutics
Mar 15, 2016 09:00AM Ligand Partner Spectrum Pharmaceuticals Receives FDA Approval of EVOMELA™ (melphalan) for Injection
Feb 10, 2016 04:01PM Ligand Reports Fourth Quarter and Full Year 2015 Financial Results
Feb 9, 2016 03:13PM Trading Radar for 2/10: Twitter (TWTR), Time Warner (TWX), Tesla (TSLA), Cisco (CSCO), Humana (HUM) Report
Feb 2, 2016 09:14AM Ligand Pharma (LGND), Tizona Therapeutics Enter OmniAb Platform License Agreement
Feb 2, 2016 09:00AM Ligand Enters Into OmniAb® Platform License Agreement with Tizona Therapeutics
Jan 22, 2016 09:00AM Ligand to Report Fourth Quarter and Full Year 2015 Results on February 10th
Jan 13, 2016 09:46AM Ligand Pharma (LGND), Emergent BioSolutions (EBS) Enter Licensing Agreement Covering OmniAb Platform
Jan 13, 2016 09:45AM Ligand Enters Into OmniAb® Platform License Agreement with Emergent BioSolutions
Dec 17, 2015 04:02PM Ligand Pharma (LGND) to Acquire OMT in $178M Deal; Guides FY17 Above Expectations
Dec 17, 2015 04:01PM Ligand to Acquire OMT, Inc., a Leader in Human Antibody Generation, for $178 Million in Cash and Stock
Dec 8, 2015 07:35AM Ligand Pharma (LGND), RODES Enter CE Program-Related Global Licensing Agreements
Dec 8, 2015 07:30AM RODES Signs Exclusive Captisol® Licensing Agreement with Ligand Pharmaceuticals for Three Programs
Nov 18, 2015 04:02PM Ligand Provides Highlights from Today’s Analyst Day Event
Nov 9, 2015 04:02PM Ligand Reports Third Quarter 2015 Financial Results
Oct 20, 2015 09:00AM Ligand to Report Third Quarter Results on November 9th
Oct 12, 2015 04:01PM Ligand to Host Analyst Day on November 18th in New York City
Sep 2, 2015 09:00AM Revolade® Receives EU Approval as First-in-Class Therapy for Patients with Severe Aplastic Anemia
Aug 4, 2015 04:01PM Matthew Korenberg to Join Ligand Pharmaceuticals as Chief Financial Officer
Aug 4, 2015 04:00PM Ligand Reports Second Quarter 2015 Financial Results
Jul 24, 2015 09:00AM Revolade® Recommended by CHMP for EU Approval to Treat Patients with Severe Aplastic Anemia, a Serious Blood Disorder
Jul 16, 2015 05:30PM Ligand to Report Second Quarter Results on August 4th
May 11, 2015 08:30AM Ligand Reports First Quarter 2015 Financial Results
May 5, 2015 08:10AM Ligand Partner Viking Therapeutics Announces Closing of Initial Public Offering
Apr 24, 2015 08:00AM Ligand to Participate in Two Upcoming Investor Conferences
Apr 23, 2015 04:06PM Ligand to Report First Quarter Results on May 11th
Apr 23, 2015 04:01PM Ligand Names Melanie J. Herman Interim Chief Financial Officer
Apr 22, 2015 12:00PM Ligand Earns Milestone from SAGE Therapeutics for SAGE-547
Apr 20, 2015 07:40AM Ligand Partner TG Therapeutics Presents Positive Pre-clinical Data on IRAK4 Compounds at the American Association for Cancer Research (AACR) Annual Meeting
Nov 15, 2013 10:59AM Notable Analyst Rating Changes 11/15: (MDRX) (BLL) (LGND) Upgraded; (BBRY) (GOGO) (K) Downgraded
Jun 20, 2013 12:23PM Streetinsider.com's Hot Lunchtime Reads 06/20: (FB) (SSYS) (LGND) (CAT) (MSFT)
View More Recent Stories